Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis

被引：0
|
作者：
Daga, Shruti [1 ]
Aletaha, Daniel [2 ]
Hsu, Benjamin [3 ]
Gilbride, Jennifer [4 ]
Christie, Jacquie [5 ]
Loza, Matthew [3 ]
Dasgupta, Bidisha [3 ]
Campbell, Kim [3 ]
Brown, Kurt [6 ]
Rao, Ravi [5 ]
Tak, Paul P. [5 ]
机构：
[1] GlaxoSmithKline, Uxbridge, Middx, England
[2] Med Univ Vienna, Div Rheumatol, Dept Med 3, Vienna, Austria
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] Sum Sq Ltd, Walkern, Herts, England
[5] GlaxoSmithKline, Stevenage, Herts, England
[6] GlaxoSmithKline, Collegeville, PA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1478
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Repeated treatments with anti-IL-6 receptor antibody (MRA) lead to an extended clinical response in rheumatoid arthritis even after cessation of MRA.
    Nishimoto, N
    Nakahara, H
    Terao, K
    Kakehi, T
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S177 - S178
  • [22] Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
    Thorne, Carter
    Takeuchi, Tsutomu
    Karpouzas, George
    Sheng, Shihong
    Kurrasch, Regina
    Fei, Kaiyin
    Hsu, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [23] Clinical efficacy of anti-IL-6 receptor monoclonal antibody tocilizumab in three patients with neuromyelitis optica
    Araki, M.
    Aranami, T.
    Matsuoka, T.
    Nakamura, M.
    Okamoto, T.
    Murata, M.
    Miyake, S.
    Yamamura, T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 417 - 417
  • [24] A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate
    Weinblatt, M.
    Mease, P.
    Mysler, E.
    Takeuchi, T.
    Drescher, E.
    Berman, A.
    Zilberstein, M.
    Xing, J.
    Emery, P.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S735 - S736
  • [25] A PHASE IIB STUDY OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL ANTIBODY) WITH OR WITHOUT METHOTREXATE IN ADULTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE
    Weinblatt, M.
    Mease, P.
    Mysler, E.
    Takeuchi, T.
    Drescher, E.
    Berman, A.
    Zilberstein, M.
    Xing, J.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 680 - 681
  • [26] Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study
    Xu, Zhenhua
    Bouman-Thio, Esther
    Comisar, Craig
    Frederick, Bart
    Van Hartingsveldt, Bart
    Marini, Joseph C.
    Davis, Hugh M.
    Zhou, Honghui
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 270 - 281
  • [27] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Kazuyuki Yoshizaki
    Norihiro Nishimoto
    Masahiro Mihara
    Tadamitsu Kishimoto
    Springer Seminars in Immunopathology, 1998, 20 : 247 - 259
  • [28] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Yoshizaki, K
    Nishimoto, N
    Mihara, M
    Kishimoto, T
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1998, 20 (1-2): : 247 - 259
  • [29] Long-Term Effect of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
    Karpouzas, George
    Takeuchi, Tsutomu
    Thorne, Carter
    Sheng, Shihong
    Kurrasch, Regina
    Fei, Kaiyin
    Hsu, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [30] Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
    Genovese, Mark C.
    Fleischmann, Roy M.
    Greenwald, Maria
    Satterwhite, Julie
    Veenhuizen, Melissa
    Xie, Li
    Berclaz, Pierre-Yves
    Myers, Stephen
    Benichou, Olivier
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) : 1461 - 1468
12345